Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Actuate TherapeuticsACTU -5.13%14 Net Cash per Share is $0.13 as of Mar. 2026, which is 99% below its 10-year median of 20.74. GuruFocus rates ACTU with a GF Score™ of 14/100. Among 803 Biotechnology companies, Actuate Therapeutics ranks worse than 65.01% on this metric.
Actuate Therapeutics (NAS:ACTU) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Actuate Therapeutics Net Cash per Share Related Terms
Actuate Therapeutics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Actuate Therapeutics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACTU vs KYNB, IGC, PLRZ: Net Cash per Share Comparison
For the Biotechnology subindustry, Actuate Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Actuate Therapeutics Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Actuate Therapeutics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Actuate Therapeutics's Price-to-Net-Cash falls into.
Actuate Therapeutics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Actuate Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actuate Therapeutics (ACTU) has a Net Cash per Share of $0.13 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Actuate Therapeutics and its competitors. This is 99% below median its historical median of 20.74. Over the past decade, Actuate Therapeutics' Net Cash per Share has ranged from 8.50 to 31.04. According to the industry distribution chart, Actuate Therapeutics ranks #522 out of 803 companies in the Biotechnology industry, placing it in the top 65%.
Is Actuate Therapeutics' Net Cash per Share too high?
Actuate Therapeutics' current Net Cash per Share of $0.13 is 99% below median its 10-year median of 20.74. Over the past 10 years, this metric has ranged from a low of 8.50 to a high of 31.04. The Biotechnology industry median Net Cash per Share is 4.97. Actuate Therapeutics' value of $0.13 is 97.4% below this industry median. Based on the distribution chart, Actuate Therapeutics ranks #522 out of 803 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Net Cash per Share compare to KYNB and IGC?
According to the Biotechnology industry distribution chart, Actuate Therapeutics ranks #522 out of 803 companies for Net Cash per Share. This places Actuate Therapeutics in the lower half of its industry. The industry median Net Cash per Share is 4.97. Actuate Therapeutics' value of $0.13 is 97.4% below this benchmark. Historically, Actuate Therapeutics' own Net Cash per Share has ranged from 8.50 to 31.04 over the past decade. While the company's 10-year median is 20.74 vs. the industry median of 4.97, Actuate Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 4.97, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Actuate Therapeutics's current Net Cash per Share of $0.13 is 97.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Actuate Therapeutics and its competitors. For the Biotechnology industry, the median Net Cash per Share is 4.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actuate Therapeutics's current Net Cash per Share is $0.13, which is 99% below median its own 10-year median of 20.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Net Cash per Share of $0.13. The current Net Cash per Share is $0.13, which is 99% below median its 10-year median of 20.74 and 97.4% below the Biotechnology industry median of 4.97. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Net Cash per Share is $0.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score
Get the complete analysis for ACTU
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACTU has been successfully added to your 
